Amylyx Pharmaceuticals (AMLX) Return on Capital Employed (2022 - 2025)
Historic Return on Capital Employed for Amylyx Pharmaceuticals (AMLX) over the last 4 years, with Q3 2025 value amounting to 0.62%.
- Amylyx Pharmaceuticals' Return on Capital Employed rose 5200.0% to 0.62% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.62%, marking a year-over-year increase of 5200.0%. This contributed to the annual value of 0.96% for FY2024, which is 10700.0% down from last year.
- Latest data reveals that Amylyx Pharmaceuticals reported Return on Capital Employed of 0.62% as of Q3 2025, which was up 5200.0% from 1.06% recorded in Q2 2025.
- Amylyx Pharmaceuticals' 5-year Return on Capital Employed high stood at 0.09% for Q4 2023, and its period low was 1.62% during Q4 2024.
- For the 4-year period, Amylyx Pharmaceuticals' Return on Capital Employed averaged around 0.69%, with its median value being 0.69% (2022).
- In the last 5 years, Amylyx Pharmaceuticals' Return on Capital Employed soared by 10700bps in 2023 and then crashed by -17200bps in 2024.
- Over the past 4 years, Amylyx Pharmaceuticals' Return on Capital Employed (Quarter) stood at 0.84% in 2022, then skyrocketed by 111bps to 0.09% in 2023, then crashed by -1816bps to 1.62% in 2024, then soared by 62bps to 0.62% in 2025.
- Its Return on Capital Employed was 0.62% in Q3 2025, compared to 1.06% in Q2 2025 and 1.22% in Q1 2025.